Tickers — T

94 tickers
Sorts the reports on this page by score, highest first.
Tetra Tech, Inc.
TTEK·Industrials
A ★★★★Buy
Current$38.83
Target$41.40
Return+6.6%
Nov 14, 2026

Tetra Tech combines specialized engineering expertise, strong cash generation, and growing water-infrastructure demand, but government funding uncertainty and moderate earnings growth constrain its near-term upside.

Score
80
TransDigm Group Incorporated
TDG·Industrials
A ★★★★Buy
Current$1,203.00
Target$1,330.28
Return+10.6%
Nov 13, 2026

TransDigm combines proprietary aerospace components, exceptional pricing power, and durable aftermarket growth with attractive long-term compounding potential, although high leverage and acquisition execution risks remain significant.

Score
81
Trevi Therapeutics, Inc.
TRVI·Healthcare
D ★Strong Sell
Current$14.82
Nov 12, 2026

Trevi Therapeutics could build a valuable chronic-cough franchise through Haduvio's late-stage clinical programs, but unproven commercialization, widening losses, clinical binary risk, and substantial dilution weaken its current investment appeal.

Score
45
Tango Therapeutics, Inc.
TNGX·Healthcare
F Avoid
Current$25.73
Nov 12, 2026

Tango Therapeutics has promising PRMT5-targeted oncology programs and substantial liquidity, but its valuation depends on unproven pivotal outcomes while persistent losses and significant shareholder dilution threaten per-share value.

Score
42
Tidewater Inc.
TDW·Energy
A ★★★★Buy
Current$78.91
Target$95.11
Return+20.5%
Nov 12, 2026

Tidewater offers attractive exposure to tightening offshore vessel supply, rising charter rates, and acquisition-driven earnings growth, although offshore spending cyclicality and integration risks could undermine the recovery.

Score
76
TG Therapeutics, Inc.
TGTX·Healthcare
B ★★★Hold
Current$65.76
Target$70.00
Return+6.4%
Nov 12, 2026

TG Therapeutics is rapidly scaling a profitable multiple sclerosis franchise with significant pipeline optionality, but its premium valuation and dependence on BRIUMVI leave limited room for commercial or clinical disappointment.

Score
67
Take-Two Interactive Software, Inc.
TTWO·Communication Services
B ★★★Hold
Current$231.31
Target$259.79
Return+12.3%
Nov 12, 2026

Take-Two's unmatched gaming franchises and imminent GTA VI launch could drive a major earnings and cash-flow inflection, but elevated expectations, uneven current profitability, and blockbuster execution risk constrain valuation upside.

Score
67
The Trade Desk, Inc.
TTD·Communication Services
A ★★★★Buy
Current$15.98
Target$20.02
Return+25.3%
Nov 12, 2026

The Trade Desk combines a defensible independent advertising platform and strong cash generation with a sharply discounted valuation, but persistent growth erosion and competition could undermine its recovery.

Score
76
Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk
TLK·Communication Services
A ★★★★Buy
Current$11.23
Target$12.98
Return+15.6%
Nov 11, 2026

Telkom's dominant network, stronger data monetization and low cash-flow multiple create an undervalued income opportunity, but mobile saturation, state influence and sustained network investment constrain growth.

Score
84
Molson Coors Beverage Company
TAP·Consumer Staples
B ★★★Hold
Current$39.85
Target$44.80
Return+12.4%
Nov 10, 2026

Molson Coors offers substantial free cash flow, attractive dividends, and discounted valuation, but persistent beer-volume declines and rising manufacturing costs threaten the durability of its earnings.

Score
73
Terreno Realty Corporation
TRNO·Real Estate
B ★★★Hold
Current$67.36
Target$69.30
Return+2.9%
Nov 10, 2026

Terreno Realty owns scarce coastal industrial properties with strong occupancy and embedded rental growth, but continued equity dilution and a premium FFO valuation constrain near-term shareholder returns.

Score
70